Catherine Pietanza, Scientific Associate Vice President at Merck, shared a post on Merck, adding:
“For many U.S. patients with muscle-invasive bladder cancer, treatment pathways have been constrained by ineligibility for standard treatment. Today’s approval adds an important new approach that can be integrated into clinical practice across diverse care settings.
This is a meaningful development for patients, caregivers, and the broader bladder cancer community.”
“We’re proud to announce the FDA approval of two new treatment combinations for certain patients with muscle-invasive Bladder Cancer (MIBC). This milestone, in collaboration with Pfizer and Astellas Pharma, is an important step in bladder cancer care for more patients.